-transparent.png){kind=logo}
The effect of the imidazole derivative Dazoxiben (400 mg daily for 1 week) on antipyrine metabolism was examined in six patients with enhanced platelet aggregation. No significant change in antipyrine saliva pharmacokinetics occurred before or after Dazoxiben treatment. The rate of formation of the three main oxidative antipyrine metabolites was similar before and after Dazoxiben. Although Dazoxiben belongs chemically to the imidazole derivatives, which exhibit inhibitory activity on drug metabolism, no influence on antipyrine disposition could be detected.
Related Publications
C Staiger, and
E Walter, and
N S Wang, and
E Schuhmacher, and
J de Vries, and
E Weber
December 1982,
Thrombosis research,
C Staiger, and
E Walter, and
N S Wang, and
E Schuhmacher, and
J de Vries, and
E Weber
December 1983,
The Journal of pharmacology and experimental therapeutics,
C Staiger, and
E Walter, and
N S Wang, and
E Schuhmacher, and
J de Vries, and
E Weber
January 1981,
Thrombosis research,
C Staiger, and
E Walter, and
N S Wang, and
E Schuhmacher, and
J de Vries, and
E Weber
October 1983,
Thrombosis and haemostasis,
C Staiger, and
E Walter, and
N S Wang, and
E Schuhmacher, and
J de Vries, and
E Weber
December 1982,
European journal of pharmacology,
C Staiger, and
E Walter, and
N S Wang, and
E Schuhmacher, and
J de Vries, and
E Weber
July 1984,
Clinical pharmacology and therapeutics,
C Staiger, and
E Walter, and
N S Wang, and
E Schuhmacher, and
J de Vries, and
E Weber
April 1983,
Thrombosis and haemostasis,
C Staiger, and
E Walter, and
N S Wang, and
E Schuhmacher, and
J de Vries, and
E Weber
January 1983,
British journal of clinical pharmacology,
C Staiger, and
E Walter, and
N S Wang, and
E Schuhmacher, and
J de Vries, and
E Weber
February 1985,
European journal of clinical investigation,
C Staiger, and
E Walter, and
N S Wang, and
E Schuhmacher, and
J de Vries, and
E Weber
February 1984,
Thrombosis and haemostasis,
